All the news Showing 10 of 53 articles from: Treatment for previous non-responders & relapsersGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources AbbVie 3-drug combination cures 92 to 96% of hepatitis C patients with cirrhosis Keith Alcorn / 22 April 2014 The largest study of new direct-acting antivirals yet conducted in people with hepatitis C genotype 1 who have compensated cirrhosis has shown that it is possible to cure between 92 and 96% ... BMS combination cures 90% of genotype 1b hepatitis C in 24 weeks Caspar Thomson / 17 April 2014 A combination of two direct-acting antivirals developed by Bristol-Myers Squibb (BMS) cured 90% of previously untreated people with genotype 1b hepatitis C infection in 24 weeks, without the need for pegylated interferon ... Sofosbuvir/ledipasvir co-formulation cures more than 90% of treatment-naive and retreated genotype 1 patients Liz Highleyman / 16 April 2014 A co-formulation of sofosbuvir and ledipasvir taken for as little as eight to twelve weeks produced high sustained response rates across the board for participants in the phase 3 ION trials, including ... European liver specialists recommend use of newest hepatitis C drugs Keith Alcorn / 12 April 2014 The European Association for the Study of the Liver (EASL) has issued new guidelines for the treatment of hepatitis C which recommend that wherever possible, patients should be treated with ... Sofosbuvir/ledipasvir is safe and effective for relapsers and hard-to-treat patients Liz Highleyman / 11 April 2014 A co-formulation of sofosbuvir and ledipasvir successfully treated a variety of difficult-to-treat patient populations including people with hepatitis C virus (HCV) genotype 3, people with decompensated cirrhosis and people who were not cured ... 88% of previous relapsers achieve hepatitis C cure with simeprevir-based triple therapy Keith Alcorn / 11 April 2014 Almost 90% of European patients who had relapsed after previous treatment with pegylated interferon and ribavirin were cured of hepatitis C after 24 weeks of treatment with the protease inhibitor simeprevir (Olysio) ... AbbVie interferon-free regimen cures 96% of treatment-experienced genotype 1 hepatitis C infections Keith Alcorn / 11 April 2014 A 12-week course of three direct-acting antivirals developed by AbbVie, plus ribavirin, cured 96.3% of treatment-experienced patients with hepatitis C genotype 1 infection, Professor Stefan Zeuzem of the JW Goethe University Hospital, Frankfurt, ... US medical societies launch new hepatitis C treatment guidelines Liz Highleyman / 30 January 2014 The American Association for the Study of Liver Diseases (AASLD), Infectious Diseases Society of America (IDSA) and International Antiviral Society-USA (IAS-USA) yesterday announced the first new hepatitis C treatment guidelines ... Daclatasvir + sofosbuvir shows high hep C cure rate, new studies underway Liz Highleyman / 22 January 2014 A dual oral regimen of daclatasvir plus sofosbuvir cured more than 90% of chronic hepatitis C patients without interferon or ribavirin, according to a report in the January 16, 2014, New England Journal of ... Faldaprevir safe and effective in HCV treatment-experienced patients Michael Carter / 13 December 2013 Triple therapy including the investigational hepatitis C virus (HCV) protease inhibitor faldaprevir is a safe and effective treatment for people who did not respond to a previous course of HCV treatment, results of ... ← Prev12345...6Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive